Why Bumble (BMBL) Stock Is Trading Up Today
Shares of online dating app Bumble (NASDAQ:BMBL) jumped 23.8% in the afternoon session after the company reported decent first quarter 2025 results which included optimistic EBITDA guidance for next quarter that blew past analysts' expectations. On the other hand, its revenue guidance for next quarter missed. Separately, Bumble named Vivek Sagi as its new Chief Technology Officer, indicating the company's focus on product innovation and AI-led features. Zooming out, we still think this was a decent quarter featuring some areas of strength.
Is now the time to buy Bumble? Access our full analysis report here, it's free.
Bumble's shares are very volatile and have had 28 moves greater than 5% over the last year. But moves this big are rare even for Bumble and indicate this news significantly impacted the market's perception of the business.
The biggest move we wrote about over the last year was 9 months ago when the stock dropped 40.8% on the news that the company reported second-quarter earnings results. Its revenue missed Wall Street's estimates, and it severely downgraded its full-year revenue guidance from 9.5% year-on-year growth to 1.5% growth. It also lowered the guidance for full year Bumble App payer net addition to 275,000 to 285,000 (vs. previous guidance of 350,000 to 400,000). The guidance implied negative net adds in Q4, which is not a good sign. Overall, this was a weaker quarter.
Bumble is down 32.5% since the beginning of the year, and at $5.38 per share, it is trading 56.3% below its 52-week high of $12.30 from May 2024. Investors who bought $1,000 worth of Bumble's shares at the IPO in February 2021 would now be looking at an investment worth $76.52.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Is Nvidia stock a massive bargain — or a massive value trap?
AI has transformed demand for computer chips and the most obvious beneficiary of that has been Nvidia (NASDAQ: NVDA). With a stock market capitalization of $3.4trn, Nvidia might not seem like an obvious bargain. But what if it is really worth that much – or potentially a lot more? I have been keen to add some Nvidia stock to my portfolio, but I do not want to overpay. After all, Nvidia has shot up 1,499% in five years! So, here is what I am doing. For some companies in which I have invested in the past, from Reckitt to Burberry, I have benefited as an investor from a market being mature. Sales of detergent or pricy trenchcoats may grow over time, but they are unlikely to shoot up year after year. That is because those firms operate in mature markets. On top of that, as they are large and long-established, it is hard for them to grow by gaining substantial market share. So, market maturity has helped me as an investor because it has made it easier for me to judge what I think the total size of a market for a product or service may be – and how much of it the company in question looks likely to have in future. Chips, by contrast, are different. Even before AI, this was still a fast-growing industry – and AI has added fuel to that fire. On top of that, Nvidia is something of a rarity. It is already a large company and generated $130bn in revenues last year. But it is not mature – rather, it continues to grow at a breathtaking pace. Its first-quarter revenue was 69% higher than in the same three months of last year. Those factors mean that it is hard to tell what Nvidia is worth. Clearly that is not only my opinion: the fact that Nvidia stock is 47% higher than in April suggests that the wider market is wrestling with the same problem. Could it be a value trap? It is possible. For example, chip demand could fall after the surge of recent years and settle down again at a much lower level. A lower cost rival could eat badly into Nvidia's market share. Trade disputes could see sales volumes fall. With a price-to-earnings (P/E) ratio of 46, just a few things like that going wrong could mean today's Nvidia stock price ends up looking like a value trap. On the other hand, think about those first-quarter growth rates. If Nvidia keeps doing as well, let alone better, its earnings could soar. In that case, the prospective P/E ratio based on today's share price could be low and the current share price a long-term bargain. I see multiple possible drivers for such an increase, such as more widespread adoption of AI and Nvidia launching even more advanced proprietary chip designs. So, I reckon the company could turn out to be either a massive bargain at today's price, or a massive value trap. The price does not offer me enough margin of safety for my comfort if the stock is indeed a value trap. So, I will wait for a more attractive valuation before buying. The post Is Nvidia stock a massive bargain — or a massive value trap? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool C Ruane has no position in any of the shares mentioned. The Motley Fool UK has recommended Burberry Group Plc, Nvidia, and Reckitt Benckiser Group Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025
Associated Press
2 hours ago
- Associated Press
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Zenas To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of Zenas pursuant and/or traceable to Zenas' registration statement for the initial public offering held on or about September 13, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 8, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zenas BioPharma, Inc. ('Zenas' or the 'Company') (NASDAQ: ZBIO) and reminds investors of the June 16, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. [ This image cannot be displayed. Please visit the source: ] Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Zenas BioPharma materially overstated the amount of time it would be able to fund its operations using existing cash and expected net proceeds from the IPO; and (2) as a result, defendants' public statements were materially false and misleading at all relevant times and negligently prepared. When the true details entered the market, the lawsuit claims that investors suffered damages. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Zenas' conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Zenas BioPharma class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit
Yahoo
2 hours ago
- Yahoo
1 Stock Down 34% This Year to Buy and Hold
Investors are withdrawing their money from stocks like Viking Therapeutics due to the current uncertainty. However, the biotech has a duo of mid-stage candidates that look incredibly promising. Though it carries above-average risk, Viking has significant upside potential. 10 stocks we like better than Viking Therapeutics › Shares of Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech, are down by 34% this year. This poor performance may suggest that recent company-specific developments have rendered the stock less attractive or that it is being affected by broader market issues. The latter is true, at least to some extent, but Viking Therapeutics' thesis has not changed significantly this year. The drugmaker remains attractive compared to most of its similarly sized peers. Here is why. Viking Therapeutics is a clinical-stage biotech. That means the company has no product on the market, generates no revenue, and is consistently unprofitable. Investors aren't too keen on buying shares of companies that fit this profile when broader equities are experiencing significant volatility due to potential macroeconomic issues. In fairness, that makes sense. Clinical-stage biotechs carry above-average risk. Their products may never see the light of day outside the clinic, and even when they do, many do not generate substantial revenue. However, Viking Therapeutics is a bit different. The company is developing medicines across several areas with high unmet needs. First, there is the drugmaker's work in the weight management space. The anti-obesity drug market has experienced significant growth in recent years. Yet, analysts continue to predict that the best is yet to come. Viking Therapeutics' leading candidate in this area, VK2735, is a dual GLP-1/GIP agonist. The only approved medicine of this kind on the market is Eli Lilly's Zepbound, an undisputed leader. Being in the same class as Zepbound doesn't guarantee VK2735's success, but it's still worth pointing out that a similar mechanism of action that led to Zepbound's breakthrough and efficacy could also prove successful for Viking Therapeutics' crown jewel. And more importantly, the investigational medicine has produced better results than almost any other mid-stage candidate in weight management, outside of those being developed by Eli Lilly and Novo Nordisk. That's impressive for a mid-cap biotech, considering significantly larger drugmakers with far more resources are trying to dominate this market. Viking Therapeutics' other mid-stage program, VK2809, performed well in patients with metabolic dysfunction-associated steatohepatitis (MASH), a disease with obesity as one of the main risk factors and whose prevalence is on the rise. However, the U.S. Food and Drug Administration approved just the first MASH medicine last year, although that will likely change soon. The point, though, is that VK2809 could join a relatively young market in a few years and generate massive sales down the road. These two candidates set Viking Therapeutics apart from other clinical-stage biotech companies. It's also worth noting that Viking Therapeutics recently signed a multiyear manufacturing agreement with privately held CordenPharma for VK2735. Per the terms of the deal, CordenPharma will manufacture more than a billion oral formulations of the medicine annually, as well as over 100 million autoinjectors and another 100 million syringes per year. Viking Therapeutics will make payments to CordenPharma, totaling $150 million through 2028. This deal highlights that Viking Therapeutics is already planning some post-commercial activity for its leading candidate. That's a great sign for investors. Viking Therapeutics is developing other candidates, including another weight management product that is still in preclinical studies. Following a similar blueprint, this product is a dual agonist that mimics the action of not just one but two gut hormones: amylin, which helps regulate blood sugar, and calcitonin, which regulates calcium levels. There is slow progress on that front, but Viking Therapeutics' commitment to innovation is impressive for such a small biotech. Now, Viking Therapeutics' most advanced programs could fail in phase 3 studies. If that happens, especially with VK2735, the stock price is likely to plummet. That's a significant risk to consider. That's why the stock is probably not suitable for risk-averse investors. However, those who are comfortable with volatility should strongly consider initiating a small position in the stock. If the business goes under, which isn't that rare for smaller biotech companies, your losses will be relatively small so long as the company makes a tiny portion of your overall portfolio. But there is significant upside potential that those who invest in Viking Therapeutics today could enjoy over the long run. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Prosper Junior Bakiny has positions in Eli Lilly, Novo Nordisk, and Viking Therapeutics. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. 1 Stock Down 34% This Year to Buy and Hold was originally published by The Motley Fool
